HighTower Advisors LLC Buys New Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

HighTower Advisors LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,456 shares of the company’s stock, valued at approximately $274,000.

Other hedge funds have also made changes to their positions in the company. Quarry LP purchased a new position in Cellebrite DI in the third quarter valued at $27,000. R Squared Ltd purchased a new position in shares of Cellebrite DI in the 4th quarter valued at about $100,000. Victory Capital Management Inc. acquired a new position in shares of Cellebrite DI during the fourth quarter worth about $234,000. Steward Partners Investment Advisory LLC increased its stake in shares of Cellebrite DI by 12.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock worth $299,000 after buying an additional 1,463 shares during the period. Finally, Y Intercept Hong Kong Ltd increased its holdings in Cellebrite DI by 35.5% in the third quarter. Y Intercept Hong Kong Ltd now owns 19,510 shares of the company’s stock valued at $329,000 after buying an additional 5,113 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Trading Up 3.0 %

Shares of CLBT opened at $19.83 on Thursday. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The firm has a market capitalization of $4.75 billion, a P/E ratio of -14.27, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The stock’s fifty day simple moving average is $20.62 and its 200 day simple moving average is $19.94.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CLBT has been the subject of a number of research analyst reports. Lake Street Capital upped their target price on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Wednesday. Finally, JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.